• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.

作者信息

Gallacher S J, Fraser W D, Logue F C, Dryburgh F J, Cowan R A, Boyle I T, Ralston S H

机构信息

University Department of Medicine, Glasgow Royal Infirmary, U.K.

出版信息

Calcif Tissue Int. 1992 Dec;51(6):419-23. doi: 10.1007/BF00296674.

DOI:10.1007/BF00296674
PMID:1333351
Abstract

In this study we retrospectively reviewed results of the first 9 days of treatment with pamidronate at doses of 30 mg (n = 13), 45 mg (n = 9), and 90 mg (n = 13) in an attempt to see what factors influenced the response of serum calcium to pamidronate. The nadir of serum calcium obtained post treatment was correlated with pretreatment levels of nephrogenous cyclic adenosine monophosphate (NcAMP), the renal tubular threshold for phosphate reabsorption (TmPO4), and the renal tubular threshold for calcium reabsorption (TmCa). Using the post treatment serum calcium levels, patients were divided into "good" and "poor" responders depending on whether a normal serum calcium was obtained. Pretreatment NcAMP was significantly correlated with the magnitude of the response of serum calcium (r = 0.45, P = 0.0001). Pretreatment NcAMP was significantly higher in the poor responders (mean +/- SEM): 65.0 +/- 9.4 nmol/liter GF (poor responders) versus 29.6 +/- 6.3 (good responders), P = 0.004. NcAMP as a predictor of the acute response of serum calcium showed a sensitivity of 93% and a specificity of 72%. Pretreatment TmPO4 was negatively correlated with the serum calcium response post treatment (r = -0.41, P = 0.003). However, though TmPO4 tended to be lower in the poor responders, this was not statistically significant [0.65 mmol/liter GF +/- 0.09 (poor responders) versus 0.76 mmol/liter GF +/- 0.06 (good responders)]. As a predictor of the acute response of serum calcium, TmPO4 was less good with a sensitivity of 70% and specificity of 58%. No significant correlation was present between TmCa and the serum calcium response.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.
Calcif Tissue Int. 1992 Dec;51(6):419-23. doi: 10.1007/BF00296674.
2
Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.对骨Paget病和恶性肿瘤高钙血症中甲状旁腺激素对帕米膦酸盐治疗反应的直接和间接评估。
Bone Miner. 1991 Feb;12(2):113-21. doi: 10.1016/0169-6009(91)90040-7.
3
Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
Lancet. 1993 Jun 26;341(8861):1611-3. doi: 10.1016/0140-6736(93)90756-7.
4
Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.伴有和不伴有骨转移的高钙血症患者对静脉注射双膦酸盐治疗的反应:甲状旁腺激素相关蛋白的作用
Br J Cancer. 1994 Jul;70(1):169-72. doi: 10.1038/bjc.1994.270.
5
Serum ionized calcium, nephrogenous and total urinary cyclic AMP and urinary phosphate in normal subjects.正常受试者的血清离子钙、肾源性和总尿环磷酸腺苷以及尿磷酸盐。
Scand J Clin Lab Invest. 1984 Apr;44(2):111-8. doi: 10.3109/00365518409161391.
6
Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
Lancet. 1989 Jul 29;2(8657):241-4. doi: 10.1016/s0140-6736(89)90429-7.
7
Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Cancer. 1994 Apr 15;73(8):2223-30. doi: 10.1002/1097-0142(19940415)73:8<2223::aid-cncr2820730831>3.0.co;2-c.
8
Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.静脉注射帕米膦酸盐治疗原发性甲状旁腺功能亢进症的高钙血症。
South Med J. 1996 Jun;89(6):637-40. doi: 10.1097/00007611-199606000-00020.
9
Nephrogenous cyclic adenosine monophosphate levels in normocalcemic cancer patients: its significance.
Horm Metab Res. 1984 Apr;16(4):204-7. doi: 10.1055/s-2007-1014743.
10
A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia.低剂量与高剂量帕米膦酸盐治疗癌症相关性高钙血症的比较。
Bone Miner. 1991 Dec;15(3):249-56. doi: 10.1016/0169-6009(91)90130-r.

引用本文的文献

1
High-dose vitamin D metabolite delivery inhibits breast cancer metastasis.高剂量维生素D代谢物递送可抑制乳腺癌转移。
Bioeng Transl Med. 2021 Oct 27;7(1):e10263. doi: 10.1002/btm2.10263. eCollection 2022 Jan.
2
Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.帕米膦酸盐。关于其在溶骨性骨转移、肿瘤引起的高钙血症及骨佩吉特病治疗中应用的综述。
Drugs Aging. 1998 Feb;12(2):149-68. doi: 10.2165/00002512-199812020-00007.
3
Decrease of serum calcium concentration and lost influence of calcium on parathyroid hormone release in a patient with primary hyperparathyroidism after treatment with diphosphonates.

本文引用的文献

1
Predictive value of derived calcium figures based on the measurement of ionised calcium.基于离子钙测量得出的衍生钙数值的预测价值。
Ann Clin Biochem. 1981 Mar;18 (Pt 2):106-9. doi: 10.1177/000456328101800210.
2
Pre-operative localisation of parathyroid tumours using neck vein catheterisation and radioimmunoassay for parathyroid hormone: the Glasgow experience.使用颈静脉插管和甲状旁腺激素放射免疫测定法对甲状旁腺肿瘤进行术前定位:格拉斯哥经验
Scott Med J. 1983 Apr;28(2):146-52. doi: 10.1177/003693308302800210.
3
The hypercalcemia of malignancy: pathogenesis and management.
Calcif Tissue Int. 1993 Nov;53(5):301-3. doi: 10.1007/BF01351832.
4
Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.伴有和不伴有骨转移的高钙血症患者对静脉注射双膦酸盐治疗的反应:甲状旁腺激素相关蛋白的作用
Br J Cancer. 1994 Jul;70(1):169-72. doi: 10.1038/bjc.1994.270.
恶性肿瘤引起的高钙血症:发病机制与治疗
Metabolism. 1982 Dec;31(12):1247-77. doi: 10.1016/0026-0495(82)90012-9.
4
Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.癌症相关性高钙血症患者的生化评估:体液性和非体液性分组的证据
N Engl J Med. 1980 Dec 11;303(24):1377-83. doi: 10.1056/NEJM198012113032401.
5
Hypercalcaemia and metastatic bone disease: is there a causal link?
Lancet. 1982 Oct 23;2(8304):903-5. doi: 10.1016/s0140-6736(82)90868-6.
6
A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression.一种与恶性高钙血症相关的甲状旁腺激素相关蛋白:克隆与表达。
Science. 1987 Aug 21;237(4817):893-6. doi: 10.1126/science.3616618.
7
Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.单次输注双膦酸盐AHPrBP治疗恶性肿瘤高钙血症的剂量反应
J Clin Oncol. 1988 May;6(5):762-8. doi: 10.1200/JCO.1988.6.5.762.
8
Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia.
Q J Med. 1988 Oct;68(258):825-34.
9
Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice.注射重组人白细胞介素1α和1β会导致正常小鼠出现高钙血症。
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5235-9. doi: 10.1073/pnas.85.14.5235.
10
Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.联合应用氨基羟丙基二膦酸盐和降钙素治疗癌症相关性高钙血症
Br Med J (Clin Res Ed). 1986 Jun 14;292(6535):1549-50. doi: 10.1136/bmj.292.6535.1549.